GlassScriptPhysician profile
Nida Jiwani
NPI 1013479047
$3,757.40
in general payments reported to CMS, 2019-2025
31 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $270 · 2023: $1,313 · 2024: $1,701 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,487.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $466.90 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Inspire Medical Systems, INC. | $461.75 | 2023-2025 | Inspire |
| Abbvie INC. | $452.67 | 2022-2025 | |
| Novo Nordisk INC | $299.23 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $259.99 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $227.29 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $222.29 | 2023-2024 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $180.66 | 2024 | Repatha, Otezla |
| Dexcom, INC. | $151.55 | 2023-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $136.29 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $108.09 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $105.54 | 2024-2025 | Venaseal, Intellis Adaptivestim |
| Boston Scientific Corporation | $100.66 | 2024-2025 | General - Pain Management |
| Idorsia Pharmaceuticals US INC | $60.73 | 2022-2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $60.68 | 2024 | Qelbree |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $49.69 | 2022-2024 | Trintellix |
| Astellas Pharma US INC | $47.16 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $45.45 | 2022 | |
| Hikma Pharmaceuticals USA | $43.47 | 2022-2024 | Ryaltris, Kloxxado, Mitigare |
| Corium, LLC | $43.31 | 2023 | Azstarys |
| Intuitive Surgical, INC. | $35.72 | 2025 | |
| Sanofi Pasteur INC. | $34.55 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $31.99 | 2023-2024 | Unithroid |
| Nevro Corp. | $27.54 | 2023 | Senza |
| Acella Pharmaceuticals, LLC | $18.80 | 2024 | NP Thyroid 60 |
| Otsuka America Pharmaceutical, INC. | $18.11 | 2022 | |
| Neos Therapeutics, LP | $14.51 | 2024 | Adzenys Xr-Odt |
| Corcept Therapeutics | $13.95 | 2024 | Korlym |
| Ibsa Pharma INC. | $13.25 | 2023 | Tirosint, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.09 | 2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nida Jiwani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.